This site is intended for healthcare professionals
A new era for epidermolysis bullosa at EADV 2023

EADV Congress 2023: A new era for epidermolysis bullosa

Amryt Pharmaceuticals sponsored
Read time: 60 mins
Last updated: 6th Feb 2024
Published:6th Feb 2024

In the second half of the pre-recorded session and interviews at EADV 2023, Professor Christine Bodemer (Paris Descartes – Paris Sorbonne University, France) and Dr Mauricio Torres (Fundación Universitaria de Ciencias de la Salud, Columbia) discuss real-world experience with birch bark extract and patient communication in clinical practice.

Translating clinical data into clinical practice

Biggest challenges for people living with EB – Impact of treatment on total body surface area

Professor Bodemer started the second half of the session discussing quality of life for people with epidermolysis bullosa (EB), results of the EASE study and real-world experience with birch bark extract. EASE was a double-blind, randomised phase 3 trial investigating birch bark extract (development name, Oleogel-S10) in people with dystrophic EB (DEB) and junctional EB (JEB)11. In the study, 41.3% of people had first complete target wound closure within 45 days with birch bark extract, compared with 28.9% with control gel11. Adverse events were observed with similar frequency in both groups11.

Professor Bodemer considers the daily priorities for people living with EB and what the results of the EASE study could mean for them. She also discusses key takeaways from her centre’s experience in France.

Experience from centre in France – Experience in the clinic and hopes for the future

Professor Bodemer presents the highlights from her pre-recorded presentation of the session at EADV 2023.

The impact of EB – Priorities for people with EB – EASE study efficacy results – EASE study safety results – Priorities for people with EB and the EASE study – Real-world experience in France – From clinical trial to real-world experience

Implications for change in EB

An open dialogue regarding wound care routine – Potential impact of birch bark extract

Dr Torres concluded the session by discussing how to really understand your patient, communication for the best chance at success, and real-world data using birch bark extract in practice. In his centre in Colombia, use of birch bark extract on EB wounds resulted in reductions in body surface area percentage (BSAP) that were consistent with the 2-year results of the EASE study12,13.

Dr Torres gives advice on how to have an open dialogue with people with EB or their caregivers, for their wound care routine. He describes the potential impact of birch bark extract on quality of life and how clinicians can educate themselves and their patients on new treatments for EB.

Advising patients starting birch bark extract – Education on new EB treatments

Dr Torres presents the highlights from his pre-recorded presentation of the session at EADV 2023.

Introduction – Know your patient – Documenting wound types and duration – Using birch bark extract in practice – Results from real-world experience


  1. Has C, Bauer JW, Bodemer C, Bolling MC, Brucknerā€Tuderman L, Diem A, et al. Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility. British Journal of Dermatology. 2020;183(4):614-627.
  2. Bardhan A, Bruckner-Tuderman L, Chapple ILC, Fine JD, Harper N, Has C, et al. Epidermolysis bullosa. Nat Rev Dis Primers. 2020;6(1):78.
  3. Filsuvez (birch bark extract) summary of product characteristics. 2022. Available at:
  4. U.S. Food & Drug Administration. FDA approves first topical gene therapy for treatment of wounds in patients with dystrophic epidermolysis bullosa. Accessed 18 October.
  5. Filsuvez (birch bark extract) prescribing information. 2023. Available at:
  6. Gretzmeier C, Pin D, Kern JS, Chen M, Woodley DT, Bruckner-Tuderman L, et al. Systemic collagen VII replacement therapy for advanced recessive dystrophic epidermolysis bullosa. Journal of Investigative Dermatology. 2022;142(4):1094-1102.e1093.
  7. Nyström A, Bornert O, Kühl T, Gretzmeier C, Thriene K, Dengjel J, et al. Impaired lymphoid extracellular matrix impedes antibacterial immunity in epidermolysis bullosa. Proc Natl Acad Sci U S A. 2018;115(4):E705-e714.
  8. Dieter K, Niebergall-Roth E, Daniele C, Fluhr S, Frank NY, Ganss C, et al. ABCB5+ mesenchymal stromal cells facilitate complete and durable wound closure in recessive dystrophic epidermolysis bullosa. Cytotherapy. 2023;25(7):782-788.
  9. Kiritsi D, Dieter K, Niebergall-Roth E, Fluhr S, Daniele C, Esterlechner J, et al. Clinical trial of ABCB5+ mesenchymal stem cells for recessive dystrophic epidermolysis bullosa. JCI Insight. 2021;6(22).
  10. NHS. Great Ormond Street Hospital for Children. Clinical trial for children with rare skin condition gets underway. Accessed 18 October.
  11. Kern JS, Sprecher E, Fernandez MF, Schauer F, Bodemer C, Cunningham T, et al. Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results from the phase III randomized double-blind phase of the EASE study. British Journal of Dermatology. 2022;188(1):12-21.
  12. Murrell D, L. Bruckner A, Sprecher E, Kiritsi D, Maher L, Cunningham T, Kern JS. BG04 Oleogel-S10 (birch triterpenes) in the treatment of epidermolysis bullosa wounds: 24-month efficacy and safety data from the EASE study. British Journal of Dermatology. 2023;188(Supplement_4).
  13. Torres-Pradilla M, Álvarez E, Novoa M, Lozano I, Trujillo M. LB1791 Oleogel-S10 (birch bark extract) in dystrophic epidermolysis bullosa: A case series evaluating the impact on wound burden over 2 years. Journal of Investigative Dermatology. 2023;143(9):B34.

This content has been developed by EPG Health, for Medthority, in collaboration with Amryt Pharmaceuticals, the sponsor of the Industry Expert Hubs held at the European Academy of Dermatology and Venereology Congress in October 2023. This content is intended for healthcare professionals only. Amryt Pharmaceuticals is a wholly owned subsidiary of CHIESI SpA and the marketing authorisation holder for Oleogel-S10 in the EU and UK.

Job bag code: VV-MED-02197

DOP: February 2024